Recordati Rare Diseases Patent-Cliff Exposure & CMS Drug Spending Portfolio

Recordati Rare Diseases (US): 10 reconciled FDA prescription therapies (26.9% 2025 to 2030 cliff risk), $145.9M 2024 CMS Part D & Medicaid spend, and 62 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies10
2025 to 2030 Patent-Cliff Revenue Exposure26.9%
Primary Portfolio LOE Date2026-01-01
2024 CMS Total Public Spend$145.9M
2024 Medicare Part D Spend$84.0M
2024 Medicaid Spend$61.9M
California HCAI SB 17 Filings62 WAC filings (max 103.5% 2-yr change)